Avanos Medical (NYSE:AVNS) Stock Rating Upgraded by ValuEngine

Avanos Medical (NYSE:AVNS) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Wednesday, ValuEngine reports.

AVNS has been the topic of several other research reports. JMP Securities restated a “hold” rating on shares of Avanos Medical in a research report on Wednesday, August 21st. Raymond James reduced their price objective on Avanos Medical from $57.00 to $48.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, Stifel Nicolaus set a $45.00 price objective on Avanos Medical and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $57.50.

Shares of NYSE AVNS traded down $0.12 during midday trading on Wednesday, hitting $36.22. The stock had a trading volume of 193,755 shares, compared to its average volume of 320,494. The company has a market capitalization of $1.73 billion, a PE ratio of 44.17 and a beta of 1.53. The stock has a 50 day simple moving average of $35.46 and a 200-day simple moving average of $40.41. Avanos Medical has a 1 year low of $31.78 and a 1 year high of $64.79. The company has a quick ratio of 2.35, a current ratio of 3.06 and a debt-to-equity ratio of 0.25.

Avanos Medical (NYSE:AVNS) last released its earnings results on Tuesday, August 6th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. The business had revenue of $172.20 million for the quarter, compared to the consensus estimate of $172.02 million. Avanos Medical had a positive return on equity of 4.18% and a negative net margin of 3.92%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 earnings per share. As a group, analysts expect that Avanos Medical will post 1.19 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Oregon Public Employees Retirement Fund increased its stake in Avanos Medical by 1.4% during the second quarter. Oregon Public Employees Retirement Fund now owns 19,250 shares of the company’s stock worth $839,000 after acquiring an additional 271 shares during the last quarter. Advisory Services Network LLC increased its stake in Avanos Medical by 39.7% during the second quarter. Advisory Services Network LLC now owns 1,203 shares of the company’s stock worth $53,000 after acquiring an additional 342 shares during the last quarter. Arizona State Retirement System increased its stake in Avanos Medical by 1.2% during the second quarter. Arizona State Retirement System now owns 34,479 shares of the company’s stock worth $1,504,000 after acquiring an additional 405 shares during the last quarter. HighTower Advisors LLC increased its stake in Avanos Medical by 7.7% during the second quarter. HighTower Advisors LLC now owns 5,983 shares of the company’s stock worth $264,000 after acquiring an additional 428 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY increased its stake in Avanos Medical by 8.1% during the first quarter. Paradigm Capital Management Inc. NY now owns 6,160 shares of the company’s stock worth $263,000 after acquiring an additional 460 shares during the last quarter. Hedge funds and other institutional investors own 94.11% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.

Read More: Market Timing

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Avanos Medical (NYSE:AVNS)

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.